公开(公告)号：US20160067349A1

公开(公告)日：2016-03-10

申请号：US14854613

申请日：2015-09-15

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: A61K47/48 ,  C07K16/30 ,  A61K45/06

CPC classification number: A61K47/48561 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6849 ,  C07K16/30 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.

Abstract translation: 针对组织因子的抗体药物偶联物。 还公开了包含抗体和抗体药物共轭物的药物组合物，以及使用抗体和抗体药物偶联物的治疗和诊断方法。

公开(公告)号：US20150259424A1

公开(公告)日：2015-09-17

申请号：US14592558

申请日：2015-01-08

Applicant: GENMAB A/S

Inventor： Janine SCHUURMAN ,  Catharina Emanuele Gerarda HAVENITH ,  Paul PARREN ,  Jan G.J. VAN DE WINKEL ,  Denise Leah WILLIAMS ,  Jørgen PETERSEN ,  Ole BAADSGAARD

IPC: C07K16/28 ,  A61K45/06 ,  A61N5/06 ,  C07K16/46 ,  G01N33/574 ,  A61K39/395 ,  C07K16/42

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/062 ,  C07K16/4258 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/56966 ,  G01N33/57492 ,  G01N33/6854 ,  G01N33/6869 ,  G01N2333/70596 ,  G01N2333/715 ,  G01N2333/7155

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了结合并抑制人CD25的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人类转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物，产生人抗体的杂交瘤和转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20150231235A1

公开(公告)日：2015-08-20

申请号：US14566279

申请日：2014-12-10

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Paul PARREN ,  Yvo GRAUS ,  Judith OPRINS ,  Michel DE WEERS ,  Martine VAN VUGT ,  Ole BAADSGAARD, D.M.Sc. ,  Steen LISBY

IPC: A61K39/395 ,  A61K31/4439 ,  A61K31/198 ,  A61K31/573 ,  A61K31/69

Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.

Abstract translation: 本发明涉及使用包含结合CD38的抗体，皮质类固醇和非皮质类固醇化学治疗剂的组合疗法治疗癌症的新方法。

公开(公告)号：US20230416403A1

公开(公告)日：2023-12-28

申请号：US18062473

申请日：2022-12-06

Applicant: Genmab A/S

Inventor： Sandra VERPLOEGEN ,  David P. E. SATIJN ,  Rene M. A. HOET ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Vibeke Miller BREINHOLT ,  Eva EHRNROOTH ,  Ole BAADSGAARD ,  Tom VINK ,  Willem Karel BLEEKER ,  Mischa HOUTKAMP ,  Maroeska OUDSHOORN ,  Rob N. DE JONG

IPC: C07K16/36 ,  A61K39/395

CPC classification number: C07K16/36 ,  A61K39/395 ,  C07K2317/565 ,  A61K2039/505

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US20230321261A1

公开(公告)日：2023-10-12

申请号：US17957302

申请日：2022-09-30

Applicant: GENMAB A/S

Inventor： Julia BOSHUIZEN ,  Esther BREIJ ,  Louise KOOPMAN ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rob DE JONG ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Daniel PEEPER ,  Paul PARREN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00 ,  A61K45/06

CPC classification number: A61K47/6803 ,  A61K39/001102 ,  A61K45/06 ,  A61K47/6801 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  A61P35/00 ,  C07K16/2863 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.

公开(公告)号：US20220389101A1

公开(公告)日：2022-12-08

申请号：US17739940

申请日：2022-05-09

Applicant: GENMAB A/S

Inventor： Rik RADEMAKER ,  Isil ALTINTAS ,  Patrick ENGELBERTS ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/32

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US20220323582A1

公开(公告)日：2022-10-13

申请号：US17502774

申请日：2021-10-15

Applicant: GENMAB A/S

Inventor： Sandra VERPLOEGEN ,  Marije OVERDIJK ,  Riemke VAN DIJKHUIZEN ,  Willem Karel BLEEKER ,  Patrick VAN BERKEL ,  Paul PARREN ,  Steen LISBY

IPC: A61K39/395 ,  A61K51/10 ,  C07K16/28 ,  A61K47/68 ,  A61K31/7088 ,  A61K35/17 ,  A61K35/76 ,  A61K38/16 ,  A61K38/19 ,  A61K45/06 ,  C07K16/18

Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.

公开(公告)号：US20220204636A1

公开(公告)日：2022-06-30

申请号：US17550288

申请日：2021-12-14

Applicant: GENMAB A/S

Inventor： Michel DE WEERS ,  Tim WALSETH ,  Jan VAN DE WINKEL ,  Tom VINK ,  Paul PARREN

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  G01N33/573

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US20210324105A1

公开(公告)日：2021-10-21

申请号：US17149019

申请日：2021-01-14

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Patrick VAN BERKEL ,  Kristin STRUMANE ,  Aran Frank LABRIJN ,  Joost J. NEIJSSEN ,  Joyce I. MEESTERS ,  Paul PARREN ,  Janine SCHUURMAN

IPC: C07K16/32 ,  C07K16/28 ,  C07K16/10 ,  C07K16/46 ,  A61K47/68 ,  A61K39/395 ,  A61K45/06

Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.

公开(公告)号：US20210155699A1

公开(公告)日：2021-05-27

申请号：US17099328

申请日：2020-11-16

Applicant: Genmab A/S

Inventor： Aran Frank LABRIJN ,  Stefan LOVERIX ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Janine SCHUURMAN ,  Ignace LASTERS

IPC: C07K16/28 ,  C07K16/00 ,  A61K39/395 ,  A61K51/10 ,  A61K47/68

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.